Rapport Therapeutics, Inc. Common Stock (RAPP)
RAPP Stock Price Chart
Explore Rapport Therapeutics, Inc. Common Stock interactive price chart. Choose custom timeframes to analyze RAPP price movements and trends.
RAPP Company Profile
Discover essential business fundamentals and corporate details for Rapport Therapeutics, Inc. Common Stock (RAPP) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
7 Jun 2024
Employees
69.00
Website
https://www.rapportrx.comCEO
Abraham N. Ceesay
Description
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
RAPP Financial Timeline
Browse a chronological timeline of Rapport Therapeutics, Inc. Common Stock corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.96, while revenue estimate is $2.22m.
Earnings released on 7 May 2026
EPS came in at -$0.42 surpassing the estimated -$0.56 by +25.00%, while revenue for the quarter reached $20.00m , beating expectations by +166.67%.
Earnings released on 10 Mar 2026
EPS came in at -$0.72 falling short of the estimated -$0.65 by -10.77%.
Earnings released on 6 Nov 2025
EPS came in at -$0.71 surpassing the estimated -$0.77 by +7.79%.
Earnings released on 7 Aug 2025
EPS came in at -$0.75 surpassing the estimated -$0.87 by +13.79%.
Earnings released on 8 May 2025
EPS came in at -$0.68 surpassing the estimated -$0.77 by +11.69%.
Earnings released on 11 Mar 2025
EPS came in at -$0.57 surpassing the estimated -$0.62 by +8.06%.
Earnings released on 7 Nov 2024
EPS came in at -$0.50 surpassing the estimated -$0.57 by +12.28%.
Earnings released on 8 Aug 2024
EPS came in at -$1.70 falling short of the estimated -$0.68 by -150.00%.
Earnings released on 31 Mar 2024
EPS came in at -$0.12 .
Earnings released on 31 Dec 2023
EPS came in at -$0.07 .
Earnings released on 30 Sept 2023
EPS came in at -$0.05 .
Earnings released on 29 Jun 2023
EPS came in at -$0.03 .
Earnings released on 31 Mar 2023
EPS came in at -$0.03 .
RAPP Stock Performance
Access detailed RAPP performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
